Home| Clinical Senior Lecturer |
Contact details:
| Tel: | +44 203 246 0339 |
| Fax: | +44 203 246 0351 |
| Email: | a.b.provan@qmul.ac.uk |
| Address: | Academic Haematology Unit,, |
Biography
Trained in genetics then medicine at Leicester University (q 1984). Junior posts in Glasgow , Nottingham and Yorkshire before taking up LRF Fellowship in Southampton in 1989. In 1993 I undertook research at The Dana-Farber Cancer Institute ( Boston , Mass) before taking up Consultant post in Southampton in 1995. In 2000 I moved to Barts & The London and worked as Senior Lecturer from 2000-2005. From June 2005 until July 2006 I worked as medical director at GlaxoSmithKline. After this one year in industry I decided to return to medicine and was appointed to Barts & The London where I took up my post from July 2006.
Research Activity
I am a general hematologist and my main interest is autoimmune haematology, particularly ITP and other immune cytopenias. I have established a UK-wide patients registry for (1) ITP, (2) Familial thrombocytopenia and (3) Evans' syndrome. The registries are being used to collect clinical data from patients with these disorders. We have DNA samples from most patients on the registries (with full informed consent) and this is being used to look for genetic markers for severity, duration of disease, responses to treatment etc, in ITP.
Key Publications
• Provan D, Newland A, Norfolk D, Bolton-Maggs P, Lilleyman J, Greer I, May A, Murphy M, Ouwehand W, Watson S. BCSH Guidelines for the investigation and management of idiopathic thrombocytopenic Purpura in adults, children and in pregnancy. British Journal of Haematology 120 , 574-596 (2003).
• Stasi R & Provan D. Management of idiopathic thrombocytopenic purpura in adults. Mayo Clinic Proceedings 79 , 504-522 (2004).
• Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC & Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. American Journal of Medicine 118 , 414-419 (2005).
• Stasi R, Amadori S, Newland AC & Provan D. Infliximab chimeric anti-tumour necrosis factor alpha monoclonal antibody as potential treatment for myelodysplastic syndromes. Leukemia 46 , 509-516 (2005).
